Methylation of the TERT promoter and risk stratification of childhood brain tumours: An integrative genomic and molecular study

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages 534-542

  Castelo Branco, Pedro ^a   Choufani, Sanaa ^a   Mack, Stephen ^a   Gallagher, Denis ^a   Zhang, Cindy ^a   Lipman, Tatiana ^a   Zhukova, Nataliya ^a   Walker, Erin J ^a   Martin, Dianna ^a   Merino, Diana ^a   Wasserman, Jonathan D ^a   Elizabeth, Cynthia ^a   Alon, Noa ^a   Zhang, Libo ^a   Hovestadt, Volker ^b   Kool, Marcel ^b   Jones, David T W ^b   Zadeh, Gelareh ^a   Croul, Sidney ^a   Hawkins, Cynthia ^a   Hitzler, Johann ^a   Wang, Jean C Y ^c   Baruchel, Sylvain ^a   Dirks, Peter B ^a   Malkin, David ^a   Pfister, Stefan ^b   Taylor, Michael D ^a   Weksberg, Rosanna ^a,d   Tabori, Uri ^a,d   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Division of Medical Oncology and Hematology   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; BRAIN TUMOR; CANADA; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILDHOOD CANCER; COHORT ANALYSIS; CPG ISLAND; DNA METHYLATION; ENZYME ACTIVITY; FOLLOW UP; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYROSEQUENCING; RISK ASSESSMENT;

AGE OF ONSET; BRAIN NEOPLASMS; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; ONTARIO; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TELOMERASE; TIME FACTORS; TRANSCRIPTION INITIATION SITE; TUMOR MARKERS, BIOLOGICAL;

EID: 84876959600     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70110-4     Document Type: Article

References (33)

1. Fearon ER, Vogelstein B A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
2. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:1850-1853.
4. Ducrest AL, Szutorisz H, Lingner J, Nabholz M Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002, 21:541-552.
5. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 2004, 22:3790-3797.
6. Tabori U, Ma J, Carter M, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 2006, 24:1522-1528.
7. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004, 22:1807-1814.
8. Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res 2011, 13:R56.
9. McDonald KL, McDonnell J, Muntoni A, et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 2010, 69:729-736.
10. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
11. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997, 3:1271-1274.
12. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 2012, 3:709-722.
13. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003, 361:836-838.
14. Wu YL, Dudognon C, Nguyen E, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 2006, 119:2797-2806.
15. Horikawa I, Barrett JC Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003, 24:1167-1176.
16. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001, 10:687-692.
17. Ng HH, Bird A DNA methylation and chromatin modification. Curr Opin Genet Dev 1999, 9:158-163.
18. Shin KH, Kang MK, Dicterow E, Park NH Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. Br J Cancer 2003, 89:1473-1478.
19. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA Methylation of the human telomerase gene CpG island. Cancer Res 2000, 60:537-541.
20. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 2002, 101:335-341.
21. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 1999, 59:6087-6090.
22. Ideraabdullah FY, Vigneau S, Bartolomei MS Genomic imprinting mechanisms in mammals. Mutat Res 2008, 647:77-85.
23. Loeb DM, Evron E, Patel CB, et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001, 61:921-925.
24. Bert SA, Robinson MD, Strbenac D, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell 2013, 23:9-22.
25. Tabori U, Vukovic B, Zielenska M, et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia 2006, 8:136-142.
26. Tabori U, Wong V, Ma J, et al. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer 2008, 99:1129-1135.
27. Castelo-Branco P, Zhang C, Lipman T, et al. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 2011, 17:111-121.
28. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999, 91:1051-1058.
29. Shay JW, Bacchetti S A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791.
30. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 2011, 6:692-702.
31. Coolen MW, Statham AL, Gardiner-Garden M, Clark SJ Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 2007, 35:e119.
32. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333:425.
33. Ridley L, Rahman R, Brundler MA, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 2008, 10:675-689.